04/09/2026
We are pleased to share that the French National Authority for Health, HAS, has issued a favourable opinion for the inclusion of The Insides System® on the List of Reimbursable Products and Services, LPPR.
This represents an important step toward long-term reimbursement and broader access to chyme reinfusion therapy for patients with type II intestinal failure in France.
We would like to thank the healthcare professionals, clinical teams and patients in France whose commitment has helped advance chyme reinfusion therapy and build the clinical evidence supporting this milestone.
Read the full announcement below:
English
https://www.theinsides.co/news/france-reimbursement
French
https://www.globenewswire.com/news-release/2026/09/01/3353851/0/fr/the-insides-company-franchit-une-nouvelle-%C3%A9tape-vers-le-remboursement-de-son-dispositif-m%C3%A9dical-the-insides-system-en-france.html